BSX:NYSEBoston Scientific Corporation Analysis

Boston Scientific trades at $57.78, comfortably above its 20‑day SMA of $56 but still under the 50‑day SMA of $61.6, signaling a short‑term pull‑back within a broader bearish trend (price well below the 200‑day SMA of $86.25). Technical momentum is mixed: RSI sits at 49 (neutral), MACD shows a bullish crossover (histogram positive) yet volume is decreasing and 30‑day volatility is high at 47%, indicating choppy price action. Fundamentally, the company is solid with 11.6% revenue growth, 68.9% gross margin and a 14.7% ROE, while debt levels remain moderate (debt‑to‑equity ~42%). However, the DCF‑derived fair value of $33.55 suggests the current price is significantly overvalued, a view reinforced by a 44% downside‑adjusted upside figure. Recent capital allocation moves – a $2 billion accelerated share‑repurchase program and a $1.5 billion investment in TAVR developer MiRus – provide short‑term price support and long‑term growth upside, but a looming securities class‑action deadline (May 4) adds legal uncertainty. Institutional interest from Lone Pine and Farallon Capital adds a positive sentiment overlay, though the lack of dividend and high price‑to‑book (3.3×) limit income‑focused appeal.